Estados Unidos - inglês - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxorubicin hydrochloride liposome injection is indicated for the treatment of aids-related kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions (5.2)]. risk summary based on findings in animals and its mechanism of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman; avoid the

Estados Unidos - inglês - NLM (National Library of Medicine)

bluepoint laboratories - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxorubicin hydrochloride liposome injection is indicated for the treatment of aids-related kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions ( 5.2)]. risk summary based on findings in animals and its mechanisms of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered t

Estados Unidos - inglês - NLM (National Library of Medicine)

dr. reddy's laboratories inc - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxorubicin hydrochloride liposome injection is indicated for the treatment of aids-related kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxorubicin hydrochloride liposome injection is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions (5.2)]. risk summary based on findings in animals and its mechanism of action, doxorubicin hydrochloride liposome injection can cause fetal harm when administered to a pregnant woman; avoid the

Malta - inglês - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents

Malta - inglês - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents

Malta - inglês - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents

Malta - inglês - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - powder for concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents

Malta - inglês - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - powder for concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents

Malta - inglês - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents

Malta - inglês - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg/ml - antineoplastic agents